drugset / Trial / NCT00633919

Efficacy of SLITone in House Dust Mite Allergic Patients

NCT00633919

Phase 2/3 Completed 124 enrolled ALK-Abelló A/S
RandomizedParallel-groupTriple-blindTreatment

Summary

This trial has been designed to evaluate the efficacy of specific immunotherapy with SLITone Dermatophagoides mix compared with placebo in subjects with house dust mite allergic asthma, based on asthma medication use during a period of 2 months with a high environmental exposure to mites (autumn 2008).

Timeline

Start
2006-07
Primary completion
2008-12
Completion
2009-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator SLITone Dermatophagoides mix Other / unclassified 200 unknown Subcutaneous
Comparator Budesonide Small molecule 64 ug Intranasal
Comparator Budesonide/formoterol Unknown 4.5 ug Inhaled
Comparator Budesonide/formoterol Unknown 80 ug Inhaled
Comparator Desloratadine Small molecule 5 mg
Comparator Prednisone Other / unclassified 5 mg Oral
Comparator Salbutamol Unknown 200 ug Inhaled

Indications